The bilateral, reversible serous maculopathy tightly linked to acalabrutinib exposure supports a drug-related etiology. BTK inhibitors should be considered in cases of new bilateral serous SRF/PEDs, and prompt coordination with oncology may facilitate recovery through systemic therapy modification.
Abbasgholizadeh et al. (2026) studied this question.